Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David A Reardon

Showing results (1-10 of 404) with videos related to

Pageof 41
Sort By:
Clinical Advances in Hematology & Oncology : H&O|July 9, 2014
Update on the use of angiogenesis inhibitors in adult patients with brain tumorsDavid A Reardon
Nature Clinical Practice. Oncology|February 8, 2006
Glioblastoma--more questions than answers?David A Reardon
The Lancet. Oncology|May 15, 2012
Treatment of elderly patients with glioblastomaDavid A Reardon
Hematology/Oncology Clinics of North America|November 21, 2021
David A Reardon
Expert Opinion on Investigational Drugs|February 27, 2009
Targeting multiple kinases in glioblastoma multiformeSith Sathornsumetee, David A Reardon
Med (New York, N.Y.)|May 19, 2022
Vaccination for IDH-mutant tumors: A novel therapeutic approach applied to gliomaDavid A Reardon, Michael Weller
Journal of Neuro-Oncology|February 25, 2015
Re-defining response and treatment effects for neuro-oncology immunotherapy clinical trialsDavid A Reardon, Hideho Okada
The Lancet. Oncology|December 4, 2018
Pseudoprogression: fact or wishful thinking in neuro-oncology?David A Reardon, Michael Weller
Neuro-Oncology|October 31, 2015
Dedication: Andrew T. ParsaDavid A Reardon, Michael Weller
Neuro-Oncology|October 31, 2015
IntroductionDavid A Reardon, Michael Weller
Pageof 41

Showing results (1-10 of 404) with videos related to

Sort By:
Pageof 41
Clinical Advances in Hematology & Oncology : H&O|July 9, 2014
Update on the use of angiogenesis inhibitors in adult patients with brain tumorsDavid A Reardon
Nature Clinical Practice. Oncology|February 8, 2006
Glioblastoma--more questions than answers?David A Reardon
The Lancet. Oncology|May 15, 2012
Treatment of elderly patients with glioblastomaDavid A Reardon
Hematology/Oncology Clinics of North America|November 21, 2021
David A Reardon
Expert Opinion on Investigational Drugs|February 27, 2009
Targeting multiple kinases in glioblastoma multiformeSith Sathornsumetee, David A Reardon
Med (New York, N.Y.)|May 19, 2022
Vaccination for IDH-mutant tumors: A novel therapeutic approach applied to gliomaDavid A Reardon, Michael Weller
Journal of Neuro-Oncology|February 25, 2015
Re-defining response and treatment effects for neuro-oncology immunotherapy clinical trialsDavid A Reardon, Hideho Okada
The Lancet. Oncology|December 4, 2018
Pseudoprogression: fact or wishful thinking in neuro-oncology?David A Reardon, Michael Weller
Neuro-Oncology|October 31, 2015
Dedication: Andrew T. ParsaDavid A Reardon, Michael Weller
Neuro-Oncology|October 31, 2015
IntroductionDavid A Reardon, Michael Weller
Pageof 41